United Kingdom· GB-APID-28791311000001103
Cyramza 100mg/10ml concentrate for solution for infusion vials
A ramucirumab product containing ramucirumab, registered in United Kingdom by Eli Lilly and Company Ltd. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Ramucirumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FG02 (ramucirumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Ramucirumab · ATC L01FG02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ramucirumab costs, country by country.
Normalised to the WHO defined daily dose (40 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ramucirumab · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- CH Switzerland$200.15
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Ramucirumab
- Manufacturer
- Eli Lilly and Company Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FG02
- ATC class
- Ramucirumab
- Defined daily dose
- 40 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5014602101541
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
141 interactions on record for ramucirumab.
Graded by severity as the source publishes them — 110 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ramucirumab · interactions on record
141 records
- 110 severe
- 31 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ramucirumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainCYRAMZA 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONEli Lilly Nederland B.V.
- United StatesCYRAMZAEli Lilly and Company
- CzechiaCYRAMZAEli Lilly Nederland B.V., Utrecht
- BelgiumCyramza 10 mg/mlEli Lilly Nederland
- SwitzerlandCyramza
- FinlandCyramza2care4 ApS
- Japanラムシルマブ（遺伝子組換え）日本イーライリリー
- IrelandCyramza 10 mg/ml Concentrate for solution for infusionEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cyramza
- Liechtenstein · Cyramza
- Norway · Cyramza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d434394e-a929-4d13-8ff5-681a198fa5e9 GET /v1/drugs/d434394e-a929-4d13-8ff5-681a198fa5e9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "28791311000001103",
"desc": "Cyramza 100mg/10ml concentrate for solution for infusion vials (Eli Lilly and Company Ltd)",
"form": "Solution for infusion",
"vpid": "28790411000001101",
"source": "dmd",
"vtm_id": "777396005",
"strength": "10 mg",
"substance": "Ramucirumab",
"ingredient": "Ramucirumab",
"supplier_code": "2075101000001100"
}See everything about ramucirumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.